Synairgen plc (OMY.F)
- Previous Close
0.0555 - Open
0.0585 - Bid 0.0630 x --
- Ask 0.0885 x --
- Day's Range
0.0585 - 0.0585 - 52 Week Range
0.0292 - 0.1072 - Volume
2,000 - Avg. Volume
214 - Market Cap (intraday)
16.289M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
www.synairgen.comRecent News: OMY.F
Performance Overview: OMY.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OMY.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OMY.F
Valuation Measures
Market Cap
15.45M
Enterprise Value
-5.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-42.87M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
10.63M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: OMY.F
OMY.F does not have Company Insights